Single-Cell Multiomics Reframes Melanoma Resistance as a Cell-State Problem
- A review of single-cell RNA-seq and spatial multiomics studies in melanoma, covering malignant cell states, immune ecosystems and microenvironment interactions.
- It focuses on drug-tolerant persister states, immune escape and resistance-linked cell-state transitions.
- It discusses how these data feed target discovery, biomarkers and combination design, and what limits clinical use.
💡 Points Based on the abstract
For target validation the useful lens is that resistance is often a reversible state, not a mutation, so a target seen only in persister cells needs a model that actually reproduces that state, which most xenograft panels don't. The gap the review flags is the hard one: a state signature isn't a drug target until you show perturbing it kills persisters, and a clinical biomarker needs a sampling schedule that catches the state before relapse.
📄 Paper · British Journal of Pharmacology ↗ Resolving melanoma heterogeneity at single-cell resolution: implications for target discovery and therapy resistance